Background
The Gleason Grade Group (GG) is essential in assessing the malignancy of prostate cancer (PCa) and is typically obtained by invasive biopsy procedures in which sampling errors could lead to inaccurately scored GGs. With the gradually recognized value of bi‐parametric magnetic resonance imaging (bpMRI) in PCa, it is beneficial to noninvasively predict GGs from bpMRI for early diagnosis and treatment planning of PCa. However, it is challenging to establish the connection between bpMRI features and GGs.
Purpose
In this study, we propose a dual attention‐guided multiscale neural network (DAMS‐Net) to predict the 5‐scored GG from bpMRI and design a training curriculum to further improve the prediction performance.
Methods
The proposed DAMS‐Net incorporates a feature pyramid network (FPN) to fully extract the multiscale features for lesions of varying sizes and a dual attention module to focus on lesion and surrounding regions while avoiding the influence of irrelevant ones. Furthermore, to enhance the differential ability for lesions with the inter‐grade similarity and intra‐grade variation in bpMRI, the training process employs a specially designed curriculum based on the differences between the radiological evaluations and the ground truth GGs.
Results
Extensive experiments were conducted on a private dataset of 382 patients and the public PROSTATEx‐2 dataset. For the private dataset, the experimental results showed that the proposed network performed better than the plain baseline model for GG prediction, achieving a mean quadratic weighted Kappa (Kw) of 0.4902 and a mean positive predictive value of 0.9098 for predicting clinically significant cancer (PPVGG>1). With the application of curriculum learning, the mean Kw and PPVGG>1 further increased to 0.5144 and 0.9118, respectively. For the public dataset, the proposed method achieved state‐of‐the‐art results of 0.5413 Kw and 0.9747 PPVGG>1.
Conclusion
The proposed DAMS‐Net trained with curriculum learning can effectively predict GGs from bpMRI, which may assist clinicians in early diagnosis and treatment planning for PCa patients.